Optimising your biopharmaceutical production process requires significant time and investment. At the same time, without precise insight into the composition of culture media, productivity suffers, timelines slip, costs increase, and regulatory approval becomes harder to achieve. What you really need at this time is clarity, speed, and scientific confidence, all delivered by a partner who understands the complexity of your process.

The Eurofins BPT network of laboratories offers advanced spent media and complex raw material analysis to support upstream process development, reduce bioprocess variability, and accelerate time-to-market. Through our proprietary Spedia-NMR™ platform, we can quickly provide a comprehensive, quantifiable view of your culture media.

Spedia-NMR™ can measure 50 types of analytes including:

• Amino acids (10 μM–100 mM)
• Common monosaccharides and organic acids (50 μM–100 mM)
• Polyamines (10 μM–100 mM)
• Water-soluble B vitamins (0.1 μM–100 μM)
• Surfactants, buffers, and methanol
• Inorganic salts and trace metals (ppm level)

These analyses are validated for mammalian cells, stem cells, bacteria, yeast (e.g., E. coli, Pichia), and insect cells. We support both chemically defined and non-chemically defined media systems—including hydrolysate and yeastolate formulations—while addressing matrix effects that typically interfere with standard testing platforms.

The clients we work today with benefit from:

• A single lab to test all relevant compositional parameters
• Absolute quantitation from low-volume samples (~1 ml)
• Turnaround times of 2–3 weeks
• Pay-per-sample flexibility
• Support for BSL-1 platforms
• High comparability of raw materials across suppliers 

Whether your goal is to improve cell line stability, increase yield, or support product filing, this targeted analytical platform delivers reliable data that empowers better decision-making and enables you to:

• Troubleshoot variability in nutrient levels and metabolite accumulation
• Prevent performance loss linked to unknown media variability
• Compare and qualify raw materials from multiple vendors
• Accelerate process development and reduce reliance on cell-based assays
• Confidently support regulatory filings with robust datasets
   

Backed by years of experience and a proven track record with leading biopharma and biotech firms, Eurofins BPT ensures your culture media decisions are based on clear evidence.